TG Therapeutics says 2024 Briumvi sales topped expectations

Citing preliminary financials, TG Therapeutics (NASDAQ:TGTX) announced Tuesday that the U.S. net sales from its multiple sclerosis therapy, Briumvi, for Q4 and full-year 2024 well exceeded its initial projections.

Following a presentation at the ongoing J.P. Morgan Healthcare Conference in San